Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ninlaro is a prescription cancer medication containing ixazomib, an oral proteasome inhibitor. It is approved for use with lenalidomide and dexamethasone in patients with multiple myeloma who have received at least one previous treatment. Multiple myeloma is a cancer involving plasma cells in the bone marrow. Ninlaro interferes with cellular protein breakdown, helping suppress cancer cell growth. Treatment is directed by an oncology specialist.
read more about ninlaro ...Ninlaro inhibits the proteasome, a cellular structure responsible for breaking down damaged or unnecessary proteins. Cancer cells, including multiple myeloma cells, depend on proteasome activity to manage protein production and cellular stress. Blocking this process causes unwanted proteins to accumulate and can trigger cancer cell death. Ixazomib acts through a different mechanism from lenalidomide and dexamethasone, which are prescribed together with Ninlaro to treat previously treated multiple myeloma.
Ninlaro is approved in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. It is not recommended for maintenance treatment or newly diagnosed multiple myeloma outside controlled clinical trials. Treatment selection depends on previous therapies, disease status, blood counts, liver function, kidney function, and overall health. An oncologist determines whether the combination regimen is appropriate and monitors treatment response.
The recommended starting dose of Ninlaro is 4 mg orally on days one, eight, and 15 of each 28-day treatment cycle. It is taken in combination with lenalidomide and dexamethasone according to their prescribed schedules. Ninlaro should be taken at least one hour before or two hours after food. Capsules must be swallowed whole without crushing, chewing, or opening them. Dose adjustments can be necessary for certain patients with kidney or liver impairment or significant adverse effects.
Common side effects include diarrhea, constipation, nausea, vomiting, swelling, and peripheral neuropathy. Ninlaro can also cause thrombocytopenia, a reduction in blood platelets that increases bleeding risk. Serious complications include severe skin reactions, liver injury, thrombotic microangiopathy, and potentially serious inflammatory conditions. Patients require regular blood count monitoring and clinical assessment. Ninlaro can harm an unborn baby, so effective contraception is necessary according to the prescribing instructions.
DailyMed - NINLARO (ixazomib) capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=038f2461-834b-4488-9ebd-863c83eef5a7. Date Accessed October 19, 2026.
Ixazomib. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548002/. Date Accessed October 19, 2026.
Ixazomib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a616008.html. Date Accessed October 19, 2026.
Ixazomib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ixazomib. Date Accessed October 19, 2026.
Ixazomib Citrate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/ixazomibcitrate. Date Accessed October 19, 2026.